Company news

Celldex Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

February 27, 2022

Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference Call

February 21, 2022

Celldex to Present at the 11th Annual SVB Leerink Global Healthcare Conference

February 9, 2022

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis

December 7, 2021

Celldex Presents Positive Preclinical Data from PD-1/ILT4 Bispecific Antibody Program CDX-585 at SITC 2021

November 11, 2021

Celldex to Participate in Upcoming Investor Conferences

November 10, 2021

Celldex Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 8, 2021

Celldex Presents Positive Data on Symptom Control and Quality of Life Measurements that Further Support CDX-0159 Clinical Benefit in Phase 1b Study in Chronic Inducible Urticaria at EADV 2021

September 28, 2021

Celldex to Present at the 2021 Cantor Virtual Global Healthcare Conference

September 23, 2021

Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Academy of Dermatology and Venereology (EADV) 30th Congress

September 22, 2021

Celldex Announces Initiation of CDX-0159 Subcutaneous Formulation Study

September 12, 2021

Celldex Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 4, 2021

Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock

July 12, 2021

Celldex Therapeutics Presents Positive Data from CDX-0159 Phase 1b Study in Chronic Inducible Urticaria at EAACI 2021

July 8, 2021

Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting

June 3, 2021

Celldex Announces Acceptance of Abstract for CDX-0159 Phase 1b Results in Inducible Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021

May 31, 2021

Celldex to Present at the Jefferies 2021 Virtual Healthcare Conference

May 25, 2021

Celldex Reports First Quarter 2021 Financial Results and Provides Corporate Update

May 5, 2021

Celldex Presents Promising Data from ILT4/PD-(L)1 Bispecific Antibody Program at AACR 2021

April 11, 2021

Celldex Reports 80% Complete Response Rate in Interim Data Update from Phase 1b study of CDX-0159 in Chronic Inducible Urticaria

March 28, 2021

Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2020 Results

March 28, 2021

Celldex Therapeutics Announces Fireside Chat Presentation at the H.C. Wainwright Global Life Sciences Conference

March 4, 2021

Celldex Therapeutics to Present at 10th Annual SVB Leerink Global Healthcare Conference

February 21, 2021

Celldex Therapeutics to Expand Development of CDX-0159 into Prurigo Nodularis (PN)

February 21, 2021

Celldex Appoints Freddy A. Jimenez, Esq. as Senior Vice President and General Counsel

January 3, 2021

Celldex Doses First Patient in Phase 1b Study of CDX-0159 in Chronic Inducible Urticaria

December 8, 2020

Celldex Therapeutics to Present at 3rd Annual Evercore ISI HealthCONx Conference

November 29, 2020

Celldex Presents Data from Oncology Portfolio at SITC 2020

November 8, 2020

Celldex Provides Corporate Update and Reports Third Quarter 2020 Results

November 4, 2020

Celldex Therapeutics Initiates Phase 1b Study of CDX-0159 in Chronic Spontaneous Urticaria

October 12, 2020

Celldex Therapeutics to Present at Upcoming Healthcare Conferences

September 9, 2020

Celldex Therapeutics Initiates Phase 1 Study of New Bispecific Product Candidate CDX-527 in Solid Tumors

August 23, 2020

Celldex Provides Corporate Update and Reports Second Quarter 2020 Results

August 5, 2020

Celldex to Report Second Quarter 2020 Financial Results and Host Corporate Update Call

August 2, 2020

Celldex Therapeutics Announces Closing of $150.0 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

June 17, 2020

Celldex Therapeutics Announces Pricing of $130.4 Million Public Offering of Common Stock

June 14, 2020

Celldex’s KIT Inhibitor CDX-0159 Demonstrates Profound, Sustained Dose-dependent Reductions in Plasma Tryptase—an Indicator of Mast Cell Burden—and a Favorable Safety Profile

June 5, 2020

Celldex Provides Corporate Update and Reports First Quarter 2020 Results

May 5, 2020

Celldex Announces Acceptance of CDX-0159 Late-Breaking Poster Presentation with Voice Over at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020

May 5, 2020

Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2019 Results

March 25, 2020

Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program

March 2, 2020

Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159

November 17, 2019

Celldex Provides Corporate Update and Reports Third Quarter 2019 Results

November 11, 2019

Celldex Presents Promising Data from CDX-0159 and CDX-527 Programs

November 10, 2019

CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study

November 7, 2019

Celldex Therapeutics Announces Upcoming Data Presentations

October 1, 2019

Celldex Therapeutics to Present at the Cantor Global Healthcare Conference

September 29, 2019

← Newer news releases

Calls

Decks

The 5 newest of 14 decks. Every deck is listed under its year.